2018 Mo-99 TOPICAL MEETING ON
MOLYBDENUM-99 PRODUCTION TECHNOLOGY DEVELOPMENT

SEPTEMBER 23-26, 2018
HILTON KNOXVILLE HOTEL
KNOXVILLE, TN

Commercial-Scale LEU Mo-99 Production Facility Utilizing Existing Technologies

Carmen I. Bigles and Ian L. Turner
Coquí Pharma
1172 South Dixie Hwy. #335
Coral Gables, FL 33146

COQUÍ PHARMA (COQUÍ) IS IN THE PROCESS OF DEVELOPING, CONSTRUCTING AND OPERATING A DEDICATED MEDICAL ISOTOPE PRODUCTION FACILITY (MIPF) AT OAK RIDGE, TENNESSEE. THE MIPF IS DESIGNED TO CREATE A RELIABLE, COMMERCIAL SCALE PRODUCTION SUPPLY OF THE MEDICAL DIAGNOSTIC RADIOISOTOPE MOLYBDENUM-99 (MO-99) WITHOUT THE USE OF HIGHLY ENRICHED URANIUM.

THIS CRITICAL MATERIAL IS THE WORLD'S MOST WIDELY USED MEDICAL RADIOISOTOPE, UTILIZED IN 80% OF ALL NUCLEAR MEDICINE PROCEDURES. ANNUALLY OVER 18 MILLION MEDICAL PROCEDURES IN THE UNITED STATES UTILIZE MO-99. CURRENTLY, THERE IS NO LARGE SCALE DOMESTIC PRODUCTION SOURCE FOR THIS MATERIAL AND ESSENTIALLY ALL MO-99 IS IMPORTED.

THE FACILITY UTILIZES EXISTING COMMERICIALLY PROVEN LOW ENRICHED URANIUM (LEU) TECHNOLOGIES. THE NUCLEAR DESIGNER IS INVAP, THE WORLD'S LEADING DESIGNER OF LEU RESEARCH NUCLEAR REACTORS AND LEU MO-99 PRODUCTION FACILITIES.

.